Literature DB >> 29479947

Is the extent of surgical resection important in patient outcome in benign and borderline phyllodes tumors of the breast?

Ali İbrahim Sevinç, Süleyman Özkan Aksoy, Merih Güray Durak, Pınar Balcı.   

Abstract

Background/aim: Phyllodes tumors (PTs) of the breast are rare, and their diagnosis and treatment remain controversial. This retrospective study aims to examine the clinical outcome of benign and borderline PTs, according to the surgical margins. Materials and methods: We examined the medical records of 122 patients in our clinic, who had histologically confirmed benign and borderline PTs between 1994 and 2017.
Results: The mean age of the patients was 40.6 years (range 18.0-81.0, ±12.1 standard deviation [SD]) and the mean tumor size was 25.8 mm (range 9-65, ±10.3 SD). All patients underwent a breast-conserving procedure and the median follow-up was 51 months. Tumor margins were positive (tumor touching the ink) in 43 patients (35%). Only 16 patients (13%) had margins ≥10 mm. The margins were between 2 and 10 mm in most patients (40%) and ≤1 mm in 12% of the patients.
Conclusion: Although no re-excision was performed to obtain grossly clear margins, local recurrence was not observed in any patients. Therefore, revision surgery for close or positive surgical margins for benign and borderline PTs should not be performed as a rule. As most tumors recur within 2 years of diagnosis, we propose a close clinical and imaging follow-up during this period.

Entities:  

Keywords:  Phyllodes tumor; surgery; surgical margins

Mesh:

Year:  2018        PMID: 29479947     DOI: 10.3906/sag-1704-47

Source DB:  PubMed          Journal:  Turk J Med Sci        ISSN: 1300-0144            Impact factor:   0.973


  7 in total

1.  Surgical margins for borderline and malignant phyllodes tumours.

Authors:  A Thind; B Patel; K Thind; J Isherwood; B Phillips; K Dhaliwal; D D Remoundos
Journal:  Ann R Coll Surg Engl       Date:  2020-01-10       Impact factor: 1.891

2.  Surgical management in phyllodes tumors of the breast: a systematic review and meta-analysis.

Authors:  Yufan Wei; Yanying Yu; Yashuang Ji; Yuting Zhong; Ningning Min; Huayu Hu; Qingyu Guan; Xiru Li
Journal:  Gland Surg       Date:  2022-03

Review 3.  Width of margins in phyllodes tumors of the breast: the controversy drags on?-a systematic review and meta-analysis.

Authors:  Arnaud Toussaint; Romain Piaget-Rossel; Coraline Stormacq; Patrice Mathevet; Karine Lepigeon; Patrick Taffé
Journal:  Breast Cancer Res Treat       Date:  2020-09-15       Impact factor: 4.872

Review 4.  High-risk lesions of the breast: concurrent diagnostic tools and management recommendations.

Authors:  Francesca Catanzariti; Daly Avendano; Giuseppe Cicero; Margarita Garza-Montemayor; Carmelo Sofia; Emmanuele Venanzi Rullo; Giorgio Ascenti; Katja Pinker-Domenig; Maria Adele Marino
Journal:  Insights Imaging       Date:  2021-05-26

Review 5.  Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

Authors:  Christoph J Rageth; Elizabeth A M O'Flynn; Katja Pinker; Rahel A Kubik-Huch; Alexander Mundinger; Thomas Decker; Christoph Tausch; Florian Dammann; Pascal A Baltzer; Eva Maria Fallenberg; Maria P Foschini; Sophie Dellas; Michael Knauer; Caroline Malhaire; Martin Sonnenschein; Andreas Boos; Elisabeth Morris; Zsuzsanna Varga
Journal:  Breast Cancer Res Treat       Date:  2018-11-30       Impact factor: 4.872

6.  Effect of Intensive Psychological Care on Patients with Benign Breast Lumps after Mammotome-Assisted Tumor Resection.

Authors:  Ping Xu; Ronghua Xu; Qingfeng Yang; Hongfeng Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-24       Impact factor: 2.650

7.  The treatment process of an extremely rare giant borderline phyllodes tumor of breast: case report and literature review.

Authors:  Qing Wang; Kai Zheng; Lei Zhang; Mingjian Tan; Hongwan Li; Hengyu Zhang; Dong Chen; Zhilin Li; Zhirui Chuan; Xi Wang; Yuanxiao Wang; Lei Zhe; Lijuan Liu; Dequan Liu; Rong Guo; Shicong Tang
Journal:  Transl Cancer Res       Date:  2021-04       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.